• Ruthenium Red: Precision Ca2+ Transport Inhibitor for Advanc

  2026-07-23

  Ruthenium Red distinguishes itself as a potent Ca2+ transport inhibitor ideal for dissecting mechanotransduction and autophagy workflows. This guide translates the latest cytoskeleton-dependent autophagy insights into actionable protocols, troubleshooting, and advanced applications—helping researchers achieve reproducible, high-impact results.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-23

  Schwartz's dissertation introduces a refined approach for evaluating anti-cancer drug responses in vitro, distinguishing proliferative arrest from cell death using fractional viability metrics. This innovation enhances the interpretability and reliability of preclinical studies, offering new methodological clarity for research on anti-proliferative agents including HDM2 inhibitors.

• Intraarticular Resiniferatoxin for Osteoarthritis Pain Relie

  2026-07-22

  This review highlights intraarticular resiniferatoxin (RTX) as a novel, mechanism-driven analgesic for osteoarthritis pain. The study synthesizes preclinical and early-phase clinical evidence showing that RTX achieves chemical inactivation of TRPV1-positive sensory neurons, offering long-lasting pain relief distinct from conventional treatments.

• DOT1L Inhibition Enhances Innate Immunity in Multiple Myelom

  2026-07-22

  The reference study demonstrates that DOT1L inhibition reprograms innate immune responses and synergistically enhances the efficacy of immunomodulatory drugs in multiple myeloma. These findings identify DOT1L as a central epigenetic vulnerability in MM and elucidate the molecular crosstalk between epigenetic regulation and anti-tumor immunity.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Pre

  2026-07-21

  DIDS is a potent anion transport inhibitor targeting chloride channels, notably ClC-Ka and ClC-ec1, with defined IC50 values. Its actions extend to TRPV1 modulation, vasodilation, and tumor suppression, making it a critical tool in physiological and translational research. APExBIO's DIDS (SKU B7675) is supplied for research purposes with rigorously defined properties and benchmarks.

• Resiniferatoxin (RTX): Ultra-Potent TRPV1 Agonist for Analge

  2026-07-21

  Resiniferatoxin (RTX) is a highly selective and ultra-potent TRPV1 agonist with analgesic efficacy 500–1000 times that of capsaicin. RTX induces persistent TRPV1 activation, leading to targeted sensory neuron desensitization and long-lasting pain relief. Its precise mechanism and clinical promise position RTX as a transformative tool in pain research and therapy.

• Dual-Action Inhibition Enhances p38α MAP Kinase Dephosphoryl

  2026-07-20

  The referenced study uncovers how certain kinase inhibitors, including those targeting p38α MAP kinase, not only inhibit kinase activity but also accelerate dephosphorylation by phosphatases. This dual-action mechanism provides new opportunities for designing selective and potent inhibitors for inflammatory disease research.

• Hexamethonium Bromide in Neuronal Signaling Pathway Research

  2026-07-20

  Hexamethonium Bromide, a selective antagonist of neuronal-type nicotinic AChRs, unlocks precise manipulation of autonomic ganglia neurotransmission. Researchers can dissect sex-specific mechanisms in hypertension models and optimize protocols for robust, reproducible data.

• Capsazepine: TRPV1 Ion Channel Antagonist in Pain Research

  2026-07-19

  Capsazepine empowers translational pain and apoptosis research with precise TRPV1 ion channel antagonism and robust workflow flexibility. Its competitive inhibition of capsaicin binding enables sophisticated dissection of nociception and apoptosis pathways, positioning it as a gold-standard tool for mechanistic studies and drug discovery.

• ARCA Cy3 EGFP mRNA (5-moUTP): Fluorescent mRNA for Imaging P

  2026-07-18

  ARCA Cy3 EGFP mRNA (5-moUTP) merges direct-detection fluorescence with immune-silent translation, streamlining mRNA delivery and localization studies in mammalian cells. This advanced tool empowers researchers to optimize transfection, track intracellular fate, and troubleshoot workflows with unprecedented clarity.

• Capsazepine in Precision Pain Modeling: TRPV1 Antagonism Rev

  2026-07-17

  Explore how Capsazepine, a potent TRPV1 ion channel antagonist, enables next-generation precision modeling of pain and apoptosis. This article uniquely connects molecular action to translational assay design, offering in-depth perspective for advanced TRPV1 channel function research.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-17

  This study by Xue et al. demonstrates pronounced sex differences in the development of angiotensin II-induced hypertension in conscious mice, with males showing a greater hypertensive response than females. The findings highlight the complex influence of sex hormones and autonomic regulation in hypertension models, shaping future experimental approaches in cardiovascular research.

• Angiotensin Peptides Modulate SARS-CoV-2 Spike–Receptor Inte

  2026-07-16

  This study reveals that naturally occurring angiotensin peptides, including variants derived from Angiotensin I, can enhance the binding of the SARS-CoV-2 spike protein to cellular receptors—particularly AXL—implicating a novel molecular link between the renin-angiotensin system and COVID-19 pathogenesis. These findings highlight the importance of peptide structure and sequence in modulating viral entry, opening new avenues for mechanistic research and therapeutic targeting.

• Berberine Hydrochloride in Gut–Bone Axis & Osteometabolic Re

  2026-07-16

  Berberine hydrochloride enables cutting-edge workflows in metabolic and bone loss research by uniquely expanding intestinal tuft cells and modulating gut–bone signaling. This article translates recent mechanistic breakthroughs into practical, stepwise protocols and troubleshooting tips, positioning APExBIO’s high-purity compound as a linchpin for translational studies in osteoimmunology and beyond.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Pro

  2026-07-15

  DIDS, a benchmark anion transport inhibitor from APExBIO, unlocks advanced manipulation of chloride and TRPV1 channels in cancer, neuroprotection, and vascular research. This guide translates recent breakthroughs into actionable protocols, troubleshooting strategies, and workflow optimizations for maximizing DIDS's translational impact.

14802 records 3/987 page Previous Next 12345 下5页 Last page